Skip Nav Destination
Issues
1 January 2013
-
Cover Image
Cover Image
Prostate cancer (PCa) is the most frequently diagnosed malignancy in elderly American men, though both incidence and associated mortality is lower in Asian compared to Western countries. Due to this difference in PCa incidence, inositol hexaphosphate (IP6), ubiquitously present in the Asian diet and a major constituent of high fiber content diets, has triggered interest for its possible chemopreventive effects in this disease. In this study, the dose-dependent effect of IP6 feeding on prostate sizes/volume and tumor vascularization (quantitatively imaged by gadolinium (Gd) uptake) was evaluated in prostate tumors of TRAMP mice. This noninvasive, in vivo imaging technique visualized the effect of IP6 on prostate tumorigenesis as a function of time. The cover shows representative DCE-MRI images of Gd uptake in prostate tumor of TRAMP mice (untreated control vs. 2% and 4% IP6-fed mice; not shown) up to 10 minutes post-Gd injection. The pseudocolor represents incremental signal intensity (blue representing highest Gd uptake) assessing tumor perfusion and permeability in prostate tumor. 2% IP6 dose was shown to exhibit significant antitumor efficacy and to suppress growth and progression of PCa via its ability to alter tumor vascularity (data/images not shown). These chemopreventive effects of IP6 against PCa could have translational potential in controlling the clinical progression of PCa in patients diagnosed at the early stage of the disease. See article by Raina et al. (beginning on page 40) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Editorial
Perspective
Research Articles
Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling
Humam Kadara; Li Shen; Junya Fujimoto; Pierre Saintigny; Chi-Wan Chow; Wenhua Lang; Zuoming Chu; Melinda Garcia; Mohamed Kabbout; You-Hong Fan; Carmen Behrens; Diane A. Liu; Li Mao; J. Jack Lee; Kathryn A. Gold; Jing Wang; Kevin R. Coombes; Edward S. Kim; Waun Ki Hong; Ignacio I. Wistuba
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.